This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the rHuEPO efficacy, the reduction in allogeneic blood use, and adverse effects of rHuEPO and RBC transfusions.
Study designs and other criteria for inclusion in the review
The chosen studies were included for reasons of sample size and methodological quality.
Sources searched to identify primary studies
The search strategy had been published elsewhere (MacLaren et al. 2004 , see 'Other Publications of Related Interest' below for bibliographic details). No details were provided in this paper.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 6 studies were included in the review.
Methods of combining primary studies
Not stated. It appears that the two main clinical trials have been evaluated independently.
Investigation of differences between primary studies
Results of the review
The only clinically relevant benefit of using rHuEPO that was demonstrated in both studies was a reduction in transfusion requirements.
In the rHuEPO group, 45 to 50.5% of the patients required between 4.61 and 4.85 RBC units per patient.
In the no rHuEPO group, 55 to 60.4% of the patients required between 6.93 and 4.98 RBC units per patient.
These data formed the principal effectiveness and outcome parameters used in the analysis.
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-years (QALYs). The EQ-5D tariffs (utility) for the ICU population were derived from published literature. The benefits were discounted at a rate of 3%.
Direct costs
The direct costs reported were those of the health service. The key resource use categories included were the average wholesale price for rHuEPO, administration costs for both rHuEPO and RBC units, and the costs of treating adverse The probability of recombinant human erythropoietin (rHuEPO) being cost-effective was 0.52 at a threshold of $50,000 per quality-adjusted life-year (QALY). The use of rHuEPO for reducing red blood cell (RBC) transfusions in heterogeneous intensive care unit (ICU) patients would appear to be cost-effective, assuming that RBC transfusions increase the risk of nosocomial bacterial infections.
CRD COMMENTARY -Selection of comparators
A do-nothing option was used as the comparator, which seems appropriate for this type of analysis. You should decide whether this could be a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence was mainly derived from two randomised controlled trials. A more detailed explanation of the patient clinical characteristics and the comparability of the intervention and control groups would have been helpful. Although the ad hoc selection of studies to populate models is common practice, a more systematic approach is desirable to ensure that the best available evidence is used.
Validity of estimate of measure of benefit
A generic outcome measure was used for the analysis. The authors appropriately adjusted the mortality and quality of life of the general population, using national statistic lifetables, by the additional mortality rate and disutility associated with being admitted to an ICU unit.
